MédiMabs is a worldwide antibody, R&D and multi-service company based in Montreal, Canada. It was founded by scientific researchers who  have recognized the limitations of existing antibody market. They have devised a strategy to increase selection and availability of antibodies as well as of selected tools for their scientific research applications. Medimabs provides research grade monoclonal and polyclonal antibodies, both novel and known, for which defined affinity and purity specifications exist. It offers varied opportunities such as de novo antibody generation,  peptide design and synthesis as well as antibody humanization. It collaborates on R&D projects,  and acts as a distributor of existing antibody catalogs.

The Medimabs’ motto, “From Researchers, for Researchers, by Researchers” is based on the company’s dedication to provide optimal satisfaction at the level of end user’s applications. To this end, MédiMabs introduces a new element to the commercialization of research grade antibodies. Through a supplemental royalty payment it secures the commitment of the provider to contribute to the technical support, thus bringing to the customer an extra level of confidence in the quality of the antibodies and opportunities MédiMabs offers.

With the trend in medical research shifting from DNA sequencing towards protein based technology, MédiMabs brings to the scientist the antibodies they require to detect and monitor proteins. Furthermore, it facilitates the elucidation of the expression and function of the multitude of novel proteins arising from the success of the human genome sequencing.

Although MédiMabs intends to respond to the needs in most medical research areas, its primary focus includes licensing in the fields of neuroscience, neurofilaments, cancer, kinases, cytoskeleton and inflammation.